LU91252I2 - Pegaptanib de préférence sous forme de son sel de sodium (MACUGENr) - Google Patents
Pegaptanib de préférence sous forme de son sel de sodium (MACUGENr)Info
- Publication number
- LU91252I2 LU91252I2 LU91252C LU91252C LU91252I2 LU 91252 I2 LU91252 I2 LU 91252I2 LU 91252 C LU91252 C LU 91252C LU 91252 C LU91252 C LU 91252C LU 91252 I2 LU91252 I2 LU 91252I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- nucleic acid
- vegf nucleic
- acid ligand
- immunogenic
- molecular weight
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
- A61K47/544—Phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dispersion Chemistry (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/739,109 US5859228A (en) | 1995-05-04 | 1996-10-25 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
US08/870,930 US6168778B1 (en) | 1990-06-11 | 1997-06-06 | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US08/897,351 US6051698A (en) | 1997-06-06 | 1997-07-21 | Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes |
PCT/US1997/018944 WO1998018480A1 (fr) | 1996-10-25 | 1997-10-17 | Complexes a base de ligands d'acide nucleique de facteur de croissance endothelial vasculaire |
Publications (1)
Publication Number | Publication Date |
---|---|
LU91252I2 true LU91252I2 (fr) | 2006-08-14 |
Family
ID=27419245
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LU91252C LU91252I2 (fr) | 1996-10-25 | 2006-06-14 | Pegaptanib de préférence sous forme de son sel de sodium (MACUGENr) |
Country Status (18)
Country | Link |
---|---|
EP (2) | EP0957929B1 (fr) |
JP (2) | JP3626503B2 (fr) |
KR (1) | KR100514929B1 (fr) |
AT (1) | ATE318143T1 (fr) |
AU (1) | AU733674B2 (fr) |
CA (1) | CA2269072C (fr) |
DE (3) | DE69735292T2 (fr) |
DK (1) | DK0957929T3 (fr) |
ES (1) | ES2259188T3 (fr) |
FR (1) | FR06C0021I2 (fr) |
GE (1) | GEP20094799B (fr) |
IL (2) | IL129497A0 (fr) |
LU (1) | LU91252I2 (fr) |
NL (1) | NL300234I2 (fr) |
NZ (1) | NZ334859A (fr) |
PT (1) | PT957929E (fr) |
RU (1) | RU2177950C2 (fr) |
WO (1) | WO1998018480A1 (fr) |
Families Citing this family (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6232071B1 (en) * | 1990-06-11 | 2001-05-15 | Gilead Sciences, Inc. | Tenascin-C nucleic acid ligands |
US6346611B1 (en) * | 1990-06-11 | 2002-02-12 | Gilead Sciences, Inc. | High affinity TGfβ nucleic acid ligands and inhibitors |
US6395888B1 (en) | 1996-02-01 | 2002-05-28 | Gilead Sciences, Inc. | High affinity nucleic acid ligands of complement system proteins |
AU782620B2 (en) * | 1991-06-10 | 2005-08-11 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
US6762290B1 (en) | 1999-07-29 | 2004-07-13 | Gilead Sciences, Inc. | High affinity vascular endothelial growth factor (VEGF) receptor nucleic acid ligands and inhibitors |
DE60026030T2 (de) * | 1999-07-14 | 2006-08-10 | Alza Corp., Mountain View | Neutrales lipopolymer und liposomale zusammensetzungen daraus |
EP2325337A1 (fr) * | 2000-09-26 | 2011-05-25 | Duke University | Aptamères d'ARN et leurs procédés d'identification |
ES2629615T3 (es) * | 2001-10-26 | 2017-08-11 | Noxxon Pharma Ag | Ácido L-nucleico modificado |
IL161327A0 (en) * | 2001-11-09 | 2004-09-27 | Eyetech Pharmaceuticals | Methods for treating ocular neovascular diseases |
US7767803B2 (en) | 2002-06-18 | 2010-08-03 | Archemix Corp. | Stabilized aptamers to PSMA and their use as prostate cancer therapeutics |
US20040110235A1 (en) | 2002-07-25 | 2004-06-10 | David Epstein | Regulated aptamer therapeutics |
US9303262B2 (en) | 2002-09-17 | 2016-04-05 | Archemix Llc | Methods for identifying aptamer regulators |
US8853376B2 (en) | 2002-11-21 | 2014-10-07 | Archemix Llc | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US8039443B2 (en) | 2002-11-21 | 2011-10-18 | Archemix Corporation | Stabilized aptamers to platelet derived growth factor and their use as oncology therapeutics |
US10100316B2 (en) | 2002-11-21 | 2018-10-16 | Archemix Llc | Aptamers comprising CPG motifs |
WO2004050899A2 (fr) | 2002-12-03 | 2004-06-17 | Archemix Corporation | Methode de selection in vitro d'acides nucleiques 2'-substitues |
FR2852606A1 (fr) * | 2003-03-18 | 2004-09-24 | Inst Nat Sante Rech Med | Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie |
EP1620547B1 (fr) | 2003-04-21 | 2014-06-18 | Archemix LLC | Aptameres stabilises lies a un facteur de croissance derive de plaquette et leur utilisation en tant qu'agents therapeutiques d'oncologie |
CL2004001996A1 (es) * | 2003-08-08 | 2005-05-06 | Eyetech Pharmaceuticals Inc | Aptameros anti-vegf (factor de crecimiento endotelial vascular) con bloqueo nucleotidico 5'-5' o 3'-3' invertido, composicion que lo contiene, util para trastornos de neovascularizacion. |
US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
EP3736335A1 (fr) | 2004-02-12 | 2020-11-11 | Archemix LLC | Agents thérapeutiques aptamères utiles dans le traitement de troubles liés à un complément |
US20050260651A1 (en) * | 2004-04-13 | 2005-11-24 | Pericles Calias | Enhanced biologically active conjugates |
US7579450B2 (en) | 2004-04-26 | 2009-08-25 | Archemix Corp. | Nucleic acid ligands specific to immunoglobulin E and their use as atopic disease therapeutics |
EP3034089A1 (fr) | 2004-11-02 | 2016-06-22 | Archemix LLC | Aptameres stabilises pour plaquettes derives du facteur de croissance et leur utilisation en tant que produits therapeutiques oncologiques |
CN101495504A (zh) | 2005-06-30 | 2009-07-29 | 阿切埃米克斯有限公司 | 用于生产全2’-修饰的核酸转录产物的材料和方法 |
US8101385B2 (en) | 2005-06-30 | 2012-01-24 | Archemix Corp. | Materials and methods for the generation of transcripts comprising modified nucleotides |
WO2007016380A2 (fr) * | 2005-07-28 | 2007-02-08 | (Osi) Eyetech, Inc. | Dispositifs et methodes d'execution de procedures sur un sein |
CN101304748A (zh) | 2005-08-22 | 2008-11-12 | 加利福尼亚大学董事会 | Tlr激动剂 |
KR100877824B1 (ko) | 2005-11-11 | 2009-01-12 | 한국생명공학연구원 | E2epf ucp-vhl 상호작용 및 그 용도 |
CA2632417A1 (fr) * | 2005-12-06 | 2007-06-14 | Domantis Limited | Ligands presentant une specificite de liaison avec l'egfr et/ou le vegf et leurs procedes d'utilisation |
CA2633063A1 (fr) * | 2005-12-16 | 2007-06-21 | Diatos | Conjugues peptidiques de penetration cellulaire pour la delivrance d'acides nucleiques dans une cellule |
EP1970078A4 (fr) * | 2006-01-11 | 2010-11-17 | Kyowa Hakko Kirin Co Ltd | Composition inhibant l'expression d'un gene cible du globe oculaire et remede pour une maladie du globe oculaire |
HUE026496T2 (en) | 2006-03-08 | 2016-06-28 | Archemix Llc | Complement-binding aptamers and anti-C5 agents for treating eye diseases |
BRPI0807196A2 (pt) * | 2007-02-07 | 2014-06-03 | Univ California | Método para prevenir ou inibir uma infecção bacteriana, vacina, composto, e, método para prevenir, tratar ou inibir a asma |
WO2009137095A2 (fr) | 2008-05-08 | 2009-11-12 | The Johns Hopkins University | Compositions et méthodes de modulation d’une réponse immunitaire |
ES2600781T3 (es) * | 2008-12-04 | 2017-02-10 | Curna, Inc. | Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf |
AU2010226434A1 (en) | 2009-03-20 | 2011-10-13 | Egen, Inc. | Polyamine derivatives |
CN102884192A (zh) | 2009-11-23 | 2013-01-16 | 国家健康与医学研究院 | 针对a型流感病毒的基质蛋白-1的适配子及其应用 |
TWI510246B (zh) | 2010-04-30 | 2015-12-01 | Molecular Partners Ag | 抑制vegf-a受體交互作用的經修飾結合性蛋白質 |
US20120082616A1 (en) * | 2010-09-24 | 2012-04-05 | Mallinckrodt Llc | Aptamer Conjugates for Targeting of Therapeutic and/or Diagnostic Nanocarriers |
EP2836597A1 (fr) | 2012-04-11 | 2015-02-18 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Aptamère de métalloprotéinase matricielle 9 (mmp-9) et ses utilisations |
US10942184B2 (en) | 2012-10-23 | 2021-03-09 | Caris Science, Inc. | Aptamers and uses thereof |
EP4170031A1 (fr) | 2012-10-23 | 2023-04-26 | Caris Science, Inc. | Aptamères et leurs utilisations |
CA2895847C (fr) | 2012-12-19 | 2019-01-08 | Caris Science, Inc. | Compositions et procedes pour le criblage d'aptameres |
WO2014148638A1 (fr) | 2013-03-22 | 2014-09-25 | 国立大学法人東京大学 | Aptamère pour il-17 et utilisation de celui-ci |
EP3628373A1 (fr) | 2013-07-12 | 2020-04-01 | IVERIC bio, Inc. | Procédés de traitement ou de prévention des affections ophtalmologiques |
WO2015031694A2 (fr) | 2013-08-28 | 2015-03-05 | Caris Science, Inc. | Sondes oligonucléotidiques et leurs utilisations |
WO2016094673A1 (fr) | 2014-12-11 | 2016-06-16 | Bayer Healthcare Llc | Traitement d'une dégénérescence maculaire liée à l'âge accompagnée d'une petite lésion de néovascularisation choroïdienne active |
US20180036409A1 (en) | 2014-12-29 | 2018-02-08 | Bonac Corporation | Composition containing nucleic acid molecule stably |
US20180066262A1 (en) | 2015-03-09 | 2018-03-08 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
AU2016287499B2 (en) | 2015-06-29 | 2022-08-04 | Caris Science, Inc. | Therapeutic oligonucleotides |
EP3328873A4 (fr) | 2015-07-28 | 2019-04-10 | Caris Science, Inc. | Oligonucléotides ciblés |
WO2017046140A1 (fr) | 2015-09-18 | 2017-03-23 | Bayer Pharma Aktiengesellschaft | Régimes de traitement de dr et rvo en fonction de l'étendue de l'ischémie rétinienne |
KR20190008843A (ko) | 2016-03-18 | 2019-01-25 | 카리스 싸이언스, 인코포레이티드 | 올리고뉴클레오티드 프로브 및 이의 용도 |
US11697851B2 (en) | 2016-05-24 | 2023-07-11 | The Regents Of The University Of California | Early ovarian cancer detection diagnostic test based on mRNA isoforms |
AU2017271579B2 (en) | 2016-05-25 | 2023-10-19 | Caris Science, Inc. | Oligonucleotide probes and uses thereof |
EP3332812A1 (fr) | 2016-12-07 | 2018-06-13 | Rheinische Friedrich-Wilhelms-Universität Bonn | Ensemble à base d'acide nucléique et utilisation de l'ensemble dans la thérapie du cancer |
TW201904610A (zh) | 2017-06-14 | 2019-02-01 | 德商拜耳製藥公司 | 用於治療新生血管型青光眼之非抗體vegf拮抗劑 |
US11931327B2 (en) | 2017-07-04 | 2024-03-19 | Daiichi Sankyo Company, Limited | Drug for retinal degenerative disease associated with photoreceptor degeneration |
WO2019210097A1 (fr) * | 2018-04-25 | 2019-10-31 | Vitrisa Therapeutics, Inc. | Aptamères ayant une stabilité, une puissance ou une demi-vie pour une sécurité et une efficacité améliorées |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE104857T1 (de) * | 1989-03-07 | 1994-05-15 | Genentech Inc | Kovalente konjugate von lipiden und oligonukleotiden. |
US5811533A (en) * | 1990-06-11 | 1998-09-22 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US6168778B1 (en) * | 1990-06-11 | 2001-01-02 | Nexstar Pharmaceuticals, Inc. | Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes |
US5849479A (en) * | 1990-06-11 | 1998-12-15 | Nexstar Pharmaceuticals, Inc. | High-affinity oligonucleotide ligands to vascular endothelial growth factor (VEGF) |
US5459015A (en) * | 1990-06-11 | 1995-10-17 | Nexstar Pharmaceuticals, Inc. | High-affinity RNA ligands of basic fibroblast growth factor |
-
1997
- 1997-10-17 KR KR10-1999-7003488A patent/KR100514929B1/ko not_active IP Right Cessation
- 1997-10-17 ES ES97912811T patent/ES2259188T3/es not_active Expired - Lifetime
- 1997-10-17 DE DE69735292T patent/DE69735292T2/de not_active Expired - Lifetime
- 1997-10-17 NZ NZ334859A patent/NZ334859A/xx not_active IP Right Cessation
- 1997-10-17 WO PCT/US1997/018944 patent/WO1998018480A1/fr active IP Right Grant
- 1997-10-17 EP EP97912811A patent/EP0957929B1/fr not_active Expired - Lifetime
- 1997-10-17 CA CA002269072A patent/CA2269072C/fr not_active Expired - Lifetime
- 1997-10-17 AU AU49904/97A patent/AU733674B2/en not_active Expired
- 1997-10-17 IL IL12949797A patent/IL129497A0/xx unknown
- 1997-10-17 GE GEAP199711120A patent/GEP20094799B/en unknown
- 1997-10-17 AT AT97912811T patent/ATE318143T1/de active
- 1997-10-17 DE DE200612000029 patent/DE122006000029I2/de active Active
- 1997-10-17 DK DK97912811T patent/DK0957929T3/da active
- 1997-10-17 RU RU99110377/04A patent/RU2177950C2/ru active
- 1997-10-17 JP JP52055398A patent/JP3626503B2/ja not_active Expired - Lifetime
- 1997-10-17 EP EP06003279A patent/EP1685842A3/fr not_active Withdrawn
- 1997-10-17 PT PT97912811T patent/PT957929E/pt unknown
- 1997-10-17 DE DE1997635292 patent/DE122006000029I1/de active Pending
-
1999
- 1999-04-19 IL IL129497A patent/IL129497A/en not_active IP Right Cessation
-
2004
- 2004-10-15 JP JP2004301813A patent/JP4160038B2/ja not_active Expired - Lifetime
-
2006
- 2006-06-14 LU LU91252C patent/LU91252I2/fr unknown
- 2006-07-03 FR FR06C0021C patent/FR06C0021I2/fr active Active
- 2006-07-20 NL NL300234C patent/NL300234I2/nl unknown
Also Published As
Publication number | Publication date |
---|---|
AU733674B2 (en) | 2001-05-24 |
EP0957929B1 (fr) | 2006-02-22 |
ATE318143T1 (de) | 2006-03-15 |
GEP20094799B (en) | 2009-10-26 |
PT957929E (pt) | 2006-06-30 |
IL129497A0 (en) | 2000-02-29 |
RU2177950C2 (ru) | 2002-01-10 |
EP0957929A1 (fr) | 1999-11-24 |
JP4160038B2 (ja) | 2008-10-01 |
CA2269072C (fr) | 2006-02-14 |
FR06C0021I2 (fr) | 2007-08-03 |
JP3626503B2 (ja) | 2005-03-09 |
EP1685842A2 (fr) | 2006-08-02 |
DE122006000029I2 (de) | 2007-11-08 |
DK0957929T3 (da) | 2006-07-03 |
NL300234I1 (nl) | 2006-09-01 |
IL129497A (en) | 2009-06-15 |
CA2269072A1 (fr) | 1998-05-07 |
KR100514929B1 (ko) | 2005-09-15 |
NZ334859A (en) | 2001-02-23 |
DE69735292T2 (de) | 2006-10-19 |
NL300234I2 (nl) | 2006-10-02 |
EP1685842A3 (fr) | 2006-11-29 |
JP2001505191A (ja) | 2001-04-17 |
AU4990497A (en) | 1998-05-22 |
FR06C0021I1 (fr) | 2006-10-13 |
KR20000052697A (ko) | 2000-08-25 |
DE69735292D1 (de) | 2006-04-27 |
JP2005046160A (ja) | 2005-02-24 |
EP0957929A4 (fr) | 2003-06-25 |
WO1998018480A1 (fr) | 1998-05-07 |
DE122006000029I1 (de) | 2006-10-19 |
ES2259188T3 (es) | 2006-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LU91252I2 (fr) | Pegaptanib de préférence sous forme de son sel de sodium (MACUGENr) | |
ATE452136T1 (de) | Nukleinsäureligand-komplexe | |
DK1042348T3 (da) | Trombocyt afledt vækstfaktor (PDGF) nukleinsyreligandkomplekser. | |
DE69834649D1 (de) | Tie ligand-homologuen | |
DE69109131D1 (de) | Verfahren zur herstellung von molekularsieben, einschliesslich zeolithen, mit metallchelat-komplexen. | |
NO885836D0 (no) | Kvantitativ metode for bestemmelse av 1,4-dihydronikotinamid-adenin-dinukleotid i opploesning. | |
DK0393502T3 (da) | Opløselige interferon-gamma-receptorer og fremgangsmåder til fremstilling heraf | |
DE3773121D1 (de) | Verfahren zum identifizieren gewebstypischer, unloeslicher cytoskelettproteine. | |
DE59008750D1 (de) | Verfahren zur Herstellung von Ironen. | |
FI890857A (fi) | Skaopenhet att placeras under arbetsbord, i synnerhet diskbord, i ett koek. | |
ATE233323T1 (de) | Verfahren zur präparation von enantiomer- angereicherten, n-derivatisierten laktamen. | |
DE69923163D1 (de) | Verfahren zur herstellung von 1,2,4-butantriol | |
DE3871591D1 (de) | Verfahren zur herstellung von 1-propargyl-2,4-dioxoimidazolidin. | |
DE59005479D1 (de) | Verfahren zur herstellung von chinophthalonderivaten. | |
DE69018261D1 (de) | Verbessertes verfahren zur herstellung von 1,2,4-triazol-5-on mit niedrigem chlorgehalt. | |
DE59001404D1 (de) | Verfahren zur herstellung kohlenstoffarmer, feinteiliger keramikpulver. | |
DE59002140D1 (de) | Verfahren zur herstellung von 2,3,5-trimethyl-p-benzochinon. | |
NO904034L (no) | Fremgangsmaate for fremstilling av 1-etylfenoksatiin-10,10-dioksyd. | |
DE69012103D1 (de) | Verfahren zur herstellung von 4,4'-diisopropylbiphenyl. | |
ATE261436T1 (de) | Verfahren zu herstellung von substituierten pyranen | |
DE58904373D1 (de) | Wasserloesliche 2-naphthol-azoverbindungen, verfahren zu ihrer herstellung und ihre verwendung als farbstoffe. | |
DE59001102D1 (de) | Verfahren zur gewinnung von trans-1,1,4,4-tetraalkyl-2-buten-1,4-diolen. | |
ES2018944A6 (es) | Metodos de preparacion de tetraclorometalatos (ii) de 3-dialquil (aril) amino-5-fenil 1,2,4-ditiazolio. | |
ATE89284T1 (de) | Aminoanthracendion-bis-platinkomplexe, nuetzlich als antitumor-agenzien. | |
DE69015797D1 (de) | Verfahren zur herstellung von 3,4,3',4'-substituierten biphenylverbindungen. |